|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM034301933 |
| 003 |
DE-627 |
| 005 |
20250126183148.0 |
| 007 |
tu |
| 008 |
231221s1987 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed25n0115.xml
|
| 035 |
|
|
|a (DE-627)NLM034301933
|
| 035 |
|
|
|a (NLM)3448923
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Tokunaga, S
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Treatment of Candida urinary tract infections with reference to serum levels of anti-Candida antibody and D-arabinitol
|
| 264 |
|
1 |
|c 1987
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.06.1988
|
| 500 |
|
|
|a Date Revised 09.12.2020
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a A clinical study was carried out on 11 patients with Candida urinary tract infection; 4 with chronic cystitis and 7 with acute pyelonephritis including 2 patients associated with candidemia. The patients received 1.5 to 6.0 g of 5-fluorocytosine (5-FC) orally daily for 6 to 22 days. The response was excellent in 6, moderate in 4 and poor in 1 case, overall efficacy rate being 90.9%. No patients showed any adverse reaction. The antibody against the Candida species was measured by an indirect hemagglutination test and the serum level of D-arabinitol, a major metabolite of Candida species, was determined by gas-liquid chromatography. A 4-fold or greater rise in anti-Candida antibody was detected in 4 of the 6 patients with pyelonephritis, including one patient associated with candidemia, 14 to 31 days following the treatment. Serum D-arabinitol levels in all of the 4 patients with pyelonephritis exceeded the detection limit of 0.2 microgram/ml before treatment. The levels decreased promptly during treatment and normalized 10 to 20 days after the start of treatment. These results suggest that 5-FC is an effective drug for Candida urinary tract infections. The determinations of anti-Candida antibody titer and serum D-arabinitol level may be clinically useful for the diagnosis of Candida pyelonephritis. In particular, the serum levels of D-arabinitol appear to be a useful parameter to follow-up the effect of anti-fungal treatment on Candida pyelonephritis
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Antibodies, Fungal
|2 NLM
|
| 650 |
|
7 |
|a Sugar Alcohols
|2 NLM
|
| 650 |
|
7 |
|a Flucytosine
|2 NLM
|
| 650 |
|
7 |
|a D83282DT06
|2 NLM
|
| 650 |
|
7 |
|a arabitol
|2 NLM
|
| 650 |
|
7 |
|a YFV05Y57M9
|2 NLM
|
| 700 |
1 |
|
|a Ohkawa, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hisazumi, H
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 33(1987), 12 vom: 31. Dez., Seite 1988-94
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:33
|g year:1987
|g number:12
|g day:31
|g month:12
|g pages:1988-94
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 33
|j 1987
|e 12
|b 31
|c 12
|h 1988-94
|